Published in Biophys J on May 12, 2006
Mechanism of islet amyloid polypeptide fibrillation at lipid interfaces studied by infrared reflection absorption spectroscopy. Biophys J (2007) 1.27
Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One (2009) 0.87
The effect of Aβ on IAPP aggregation in the presence of an isolated β-cell membrane. J Mol Biol (2012) 0.85
Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis. Int J Mol Sci (2013) 0.82
Pressure and temperature stability of the main apple allergen Mal d1. Eur Biophys J (2010) 0.81
Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils. Sci Rep (2015) 0.80
Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites. PLoS One (2012) 0.79
Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. Biophys J (2016) 0.75
The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses. J Biol Chem (2014) 0.75
Rosin Surfactant QRMAE Can Be Utilized as an Amorphous Aggregate Inducer: A Case Study of Mammalian Serum Albumin. PLoS One (2015) 0.75
The impact of solubility and electrostatics on fibril formation by the H3 and H4 histones. Protein Sci (2011) 0.75
MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors. PLoS One (2017) 0.75
Stable misfolded states of human serum albumin revealed by high-pressure infrared spectroscopic studies. Eur Biophys J (2008) 0.75
Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Adv Protein Chem (1986) 9.79
Examination of the secondary structure of proteins by deconvolved FTIR spectra. Biopolymers (1986) 6.61
Proteins associated with the thyroid hormones. Physiol Rev (1960) 5.20
Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol (1978) 4.47
The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry (1996) 3.42
Cold denaturation of proteins. Crit Rev Biochem Mol Biol (1990) 3.42
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry (1992) 3.19
Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A (1990) 2.87
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
FTIR reveals structural differences between native beta-sheet proteins and amyloid fibrils. Protein Sci (2004) 2.31
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A (2002) 2.25
Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci (2000) 2.23
Familial amyloidotic polyneuropathy. Trends Neurosci (1989) 1.89
An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry (2001) 1.85
High pressure effects on protein structure and function. Proteins (1996) 1.78
Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem (1997) 1.76
Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry (1998) 1.72
Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat (2001) 1.67
Revisiting volume changes in pressure-induced protein unfolding. Biochim Biophys Acta (2002) 1.62
Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry (1995) 1.59
High pressure effects on biological macromolecules: from structural changes to alteration of cellular processes. Biochim Biophys Acta (2002) 1.39
Lower kinetic limit to protein thermal stability: a proposal regarding protein stability in vivo and its relation with misfolding diseases. Proteins (2000) 1.37
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry (2003) 1.36
Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry (1993) 1.35
A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J Mol Biol (2000) 1.34
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Guanidine hydrochloride-induced denaturation and refolding of transthyretin exhibits a marked hysteresis: equilibria with high kinetic barriers. Biochemistry (1997) 1.24
Aggregation of bovine insulin probed by DSC/PPC calorimetry and FTIR spectroscopy. Biochemistry (2003) 1.21
The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proc Natl Acad Sci U S A (2000) 1.21
Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. J Mol Biol (2002) 1.18
Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy. J Biol Chem (2003) 1.16
Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid (2000) 1.13
Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions. Biochemistry (2003) 1.08
Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. J Mol Biol (2003) 1.05
Hydration and packing effects on prion folding and beta-sheet conversion. High pressure spectroscopy and pressure perturbation calorimetry studies. J Biol Chem (2004) 1.04
Fourier transform infrared spectroscopy in high-pressure studies on proteins. Biochim Biophys Acta (2002) 1.03
Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. J Struct Biol (2000) 1.01
Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. J Mol Biol (2000) 1.00
Characterization of the pressure-induced intermediate and unfolded state of red-shifted green fluorescent protein--a static and kinetic FTIR, UV/VIS and fluorescence spectroscopy study. J Mol Biol (2003) 0.98
Cold denaturation of a repressor-operator complex: the role of entropy in protein-DNA recognition. Proc Natl Acad Sci U S A (1994) 0.98
Neurodegeneration in familial amyloid polyneuropathy: from pathology to molecular signaling. Prog Neurobiol (2003) 0.97
High hydrostatic pressure dissociates early aggregates of TTR105-115, but not the mature amyloid fibrils. J Mol Biol (2005) 0.96
New insights into the mechanisms of protein misfolding and aggregation in amyloidogenic diseases derived from pressure studies. Biochemistry (2004) 0.95
Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. Biophys Chem (2000) 0.92
Solid-state infrared absorption spectra and chain arrangement in some synthetic homooligopeptides in the intermolecularly hydrogen-bonded pleated-sheet beta-conformation. Biopolymers (1977) 0.91
Decreased thermodynamic stability as a crucial factor for familial amyloidotic polyneuropathy. J Mol Biol (2002) 0.85
Native state hydrogen exchange study of suppressor and pathogenic variants of transthyretin. J Mol Biol (2002) 0.84
Polymorphism of Rhesus monkey serum prealbumin. Purification and partial structure. J Biol Chem (1973) 0.81
Differences between the pressure- and temperature-induced denaturation and aggregation of beta-lactoglobulin A, B, and AB monitored by FT-IR spectroscopy and small-angle X-ray scattering. Biochemistry (1999) 0.81
Thyroxine binding to transthyretin (TTR) variants--two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. Eur J Endocrinol (1996) 0.80
High pressure, an alternative approach to understand protein misfolding diseases. Cell Mol Biol (Noisy-le-grand) (2004) 0.78
Adapting proteostasis for disease intervention. Science (2008) 13.22
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23
Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell (2006) 5.01
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
Functional amyloid--from bacteria to humans. Trends Biochem Sci (2007) 4.50
Functional amyloid formation within mammalian tissue. PLoS Biol (2006) 3.92
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell (2008) 3.11
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science (2003) 2.63
An experimental survey of the transition between two-state and downhill protein folding scenarios. Proc Natl Acad Sci U S A (2008) 2.57
Context-dependent contributions of backbone hydrogen bonding to beta-sheet folding energetics. Nature (2004) 2.44
Structure-function-folding relationship in a WW domain. Proc Natl Acad Sci U S A (2006) 2.28
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res (2005) 2.25
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A (2002) 2.25
Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem Biol (2006) 2.25
Tuning the free-energy landscape of a WW domain by temperature, mutation, and truncation. Proc Natl Acad Sci U S A (2003) 2.15
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry (2004) 2.08
Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol (2011) 2.08
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
An adaptable standard for protein export from the endoplasmic reticulum. Cell (2007) 1.86
ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol (2003) 1.82
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol (2004) 1.76
Intriguing nucleic-acid-binding features of mammalian prion protein. Trends Biochem Sci (2008) 1.74
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1. Mol Cell (2006) 1.71
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol (2005) 1.68
Amyloidogenic self-assembly of insulin aggregates probed by high resolution atomic force microscopy. Biophys J (2004) 1.65
Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov (2002) 1.63
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol (2010) 1.62
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 1.62
Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol (2006) 1.60
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des (2008) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem (2004) 1.54
The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc Natl Acad Sci U S A (2009) 1.54
Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry (2008) 1.51
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest (2004) 1.50
Engineering a beta-sheet protein toward the folding speed limit. J Phys Chem B (2005) 1.49
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol (2008) 1.42
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41
A fundamental protein property, thermodynamic stability, revealed solely from large-scale measurements of protein function. Proc Natl Acad Sci U S A (2012) 1.39
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl (2003) 1.39
Localized thermodynamic coupling between hydrogen bonding and microenvironment polarity substantially stabilizes proteins. Nat Struct Mol Biol (2009) 1.37
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry (2003) 1.36
Visualizing association of N-ras in lipid microdomains: influence of domain structure and interfacial adsorption. J Am Chem Soc (2006) 1.35
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid (2006) 1.34
The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry (2005) 1.32
Heparin accelerates gelsolin amyloidogenesis. Biochemistry (2006) 1.31
Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J (2007) 1.29
N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. J Biol Chem (2009) 1.28
Protein native-state stabilization by placing aromatic side chains in N-glycosylated reverse turns. Science (2011) 1.27
Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry (2005) 1.26
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem (2012) 1.26
Toward assessing the position-dependent contributions of backbone hydrogen bonding to beta-sheet folding thermodynamics employing amide-to-ester perturbations. J Am Chem Soc (2004) 1.26
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26
Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol (2010) 1.26
Toward quantification of protein backbone-backbone hydrogen bonding energies: An energetic analysis of an amide-to-ester mutation in an alpha-helix within a protein. Protein Sci (2008) 1.26
The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry (2007) 1.25
NMR solution structure of the isolated Apo Pin1 WW domain: comparison to the x-ray crystal structures of Pin1. Biopolymers (2002) 1.24
Probing the folding transition state structure of the villin headpiece subdomain via side chain and backbone mutagenesis. J Am Chem Soc (2009) 1.23
Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry (2003) 1.22
Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem (2002) 1.22
Aggregation of bovine insulin probed by DSC/PPC calorimetry and FTIR spectroscopy. Biochemistry (2003) 1.21
Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res (2006) 1.20
Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem (2005) 1.19
Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol. Chembiochem (2009) 1.18
Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc (2005) 1.18
X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J Biol Chem (2005) 1.18
Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. J Med Chem (2007) 1.17
Backbone-Backbone H-Bonds Make Context-Dependent Contributions to Protein Folding Kinetics and Thermodynamics: Lessons from Amide-to-Ester Mutations. Adv Protein Chem (2005) 1.16
Temperature- and pressure-induced unfolding and refolding of ubiquitin: a static and kinetic Fourier transform infrared spectroscopy study. Biochemistry (2002) 1.16
Influence of the N-terminal domain on the aggregation properties of the prion protein. Protein Sci (2005) 1.16
Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J Am Chem Soc (2013) 1.15
The effect of backbone cyclization on the thermodynamics of beta-sheet unfolding: stability optimization of the PIN WW domain. J Am Chem Soc (2002) 1.15
Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. J Mol Biol (2005) 1.14
Discovery and characterization of a mammalian amyloid disaggregation activity. Protein Sci (2010) 1.13
Insulin forms amyloid in a strain-dependent manner: an FT-IR spectroscopic study. Protein Sci (2004) 1.13
Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection. Aging Cell (2009) 1.13
Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci U S A (2005) 1.12
Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J Am Chem Soc (2003) 1.12
Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells. J Biol Chem (2008) 1.11
Small molecule oxidation products trigger disease-associated protein misfolding. Acc Chem Res (2006) 1.11
A biomimetic synthesis of thiazolines using hexaphenyloxodiphosphonium trifluoromethanesulfonate. Angew Chem Int Ed Engl (2003) 1.11
Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Lab Invest (2003) 1.10
Structural insights into the interaction between prion protein and nucleic acid. Biochemistry (2006) 1.10